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Abstract
The treatment of advanced pancreatic cancer has not 
moved much beyond single agent gemcitabine until re-
cently when protocols such as FOLFIRINOX (fluorouracil, 
leucovorin, irinotecan and oxaliplatin) and nab-paclitaxel-
gemcitabine have demonstrated some improved out-
comes. Advances in technology especially in massively 
parallel genome sequencing has progressed our under-
standing of the biology of pancreatic cancer especially 
the candidate signalling pathways that are involved in 
tumourogenesis and disease course. This has allowed 
identification of potentially actionable mutations that 
may be targeted by new biological agents. The hetero-
geneity of pancreatic cancer makes tumour tissue collec-
tion important with the aim of being able to personalise 
therapies for the individual as opposed to a one size fits 
all approach to treatment of the condition. This paper 
reviews the developments in this area of translational re-
search and the ongoing clinical studies that will attempt 
to move this into the everyday oncology practice.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: State of art review of genomic developments 
in pancreatic cancer that will hopefully lead to a new 
treatment paradigm of recognising that pancreatic 
cancer is a heterogenous disease. Adequate tissue col-
lection is important to allow biomarker testing and mo-
lecular sequencing to allow determination of actionable 
mutations so that personalised therapies can be used in 
a rational manner.
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INTRODUCTION
Until recently, progress in understanding of  pancreas 
cancer has been frustratingly slow. Prognosis remains ex-
ceedingly poor, with the majority of  patients presenting 
with rapidly lethal advanced disease[1,2]. Distinct pheno-
types, while clinically recognised, have been difficult to 
capture using common diagnostic tests. In addition, the 
value of  doing so for directing therapy has been minimal, 
with limited treatment options and a lack of  alternatives 
to gemcitabine which has remained the standard of  care 
for advanced disease until recently.
Advances in technology have recently accelerated 
our understanding of  the biology of  pancreatic cancer 
and tumour-host interactions. Recent initiatives such as 
Australian Pancreatic Cancer Genome Initiative (APGI, 
http://www.pancreaticcancer.net.au/apgi) and Interna-
tional Cancer Genome Consortium (ICGC, http://icgc.
org) have seen major progress in the acquisition of  high 
quality biospecimens for molecular studies in comprehen-
sive cancer cohorts. Whole genome sequencing has fa-
cilitated identification of  potentially actionable mutations 
with greater sensitivity and specificity. As tissue require-
ments and costs for genome sequencing decrease, the 
potential to select treatments in a “personalised” manner 
based on tumour biology moves closer to the clinic[3].
The move towards ‘‘personalised’’ treatment of  pan-
creatic cancer is not without challenges. The anatomical 
location of  the pancreas and clinical presentation of  the 
majority of  cancers in advanced stages present particular 
barriers to diagnostic and exploratory tissue sampling. 
The relative inaccessibility of  the pancreas, compared to 
many other tumour types, limits the ability to collect ad-
equate µ-tissue (for example core biopsies) from primary 
lesions. Recent trials have demonstrated that core biop-
sies are currently feasible in some settings; the Liberal 
Education and America’s Promise (LEAP) trial required 
core biopsy for trial participation and were able to do this 
prior to enrolment in 367 participants with metastatic dis-
ease[4]. Patients presenting de novo with advanced disease 
can rapidly deteriorate and any additional diagnostic tests 
need to demonstrate therapeutic value and provide useful 
information with minimal delay to be useful in routine 
practice.
Tumour and patient profiling are critical in understanding 
the disease, developing new treatments, and better select-
ing patients for existing treatments. The timely, accurate 
and appropriate collection of  tissue and blood samples 
are fundamental to driving future research and evolving 
patient care in the era of  personalised and precision med-
icine. Future strategies, including profiling of  circulating 
tumour DNA[5], may minimise the invasiveness of  testing 
but at present access to tumour tissue remains important 
in developing new treatment strategies and understanding 
their failures.
This review highlights recent advances in understand-
ing of  pancreas cancer at a molecular level including key 
signalling pathways and markers of  treatment sensitivity. 
The current evidence base for a personalised approach is 
summarised, together with relevant ongoing trials. 
RECENT ADVANCES IN SYSTEMIC 
THERAPY FOR ADVANCED PANCREATIC 
CANCER
Very little progress has been made in the systemic treat-
ment of  advanced pancreatic cancer until recent years. 
Gemcitabine a nucleoside analogue became established 
as the standard therapy following the demonstration 
of  improved survival and clinical benefit (pain, perfor-
mance status and weight) against 5-fluorouracil[6]. This 
led to the subsequent focus on combining other drugs 
with gemcitabine to test doublets against gemcitabine 
monotherapy. For a time no doublet was clearly superior 
to monotherapy. A number of  meta-analysis of  gem-
citabine combination studies have been carried out[7-9]. 
These have shown an improvement in survival with plat-
inum based combinations as well as fluorouracil based 
combinations[10]. There was a suggestion of  more benefit 
from combination therapy in good performance status 
patients and a worse prognosis in poor performance pa-
tients with combination therapy[8]. The most recent me-
ta-analysis of  26 studies with a total of  8808 patients has 
found that the relative risk of  1 year survival was lower 
for monotherapy when compared to combinations with 
platinum, fluoropyrimidine and targeted agents respec-
tively but no statistical differences were found[9]. When 
median progression free survival and overall survival 
were assessed only fluoropyrimidine was statistically su-
perior. The combination therapies were associated with 
more toxicity.
A non-gemcitabine based intensive chemotherapy 
schedule FOLFIRINOX (fluorouracil, leucovorin, iri-
notecan and oxaliplatin) in good performance status 
patients under 76 years of  age has shown clear superior-
ity to gemcitabine monotherapy (response rate 31.6% vs 
9.4% (P < 0.001), median survival 11.1 mo vs 6.8 mo (P 
< 0.01) and one year survival 48.4% vs 20.6% at a cost 
of  increased toxicity[11]. Quality of  life was assessed in 
the study and it was found that the FOLFIRINOX arm 
improved global health status and the time until definitive 
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deterioration was significantly longer than gemcitabine[12].
A recently reported phase Ⅲ trial demonstrated for 
the first time an overall survival benefit with gemcitabine 
based doublet therapy. The MPACT trial randomised 
gemcitabine vs gemcitabine plus nab-paclitaxel (Abraxane) 
found an improvement in median survival from 6.7 to 8.5 
mo with 1 year survivals of  22% and 35% respectively (P 
< 0.001)[13]. The response rate also increased in the com-
bination arm (7% vs 23%, P > 0.001), although this was 
at the expense of  higher rates of  myelosupression and 
peripheral neuropathy with the doublet.
The role of  biological agents has been studied in pan-
creatic cancer. They have generally been tested in com-
bination with the traditional chemotherapy backbone of  
gemcitabine. One positive trial was the combination of  
gemcitabine with the epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor erlotinib vs gemcitabine 
alone[14]. This NCIC phase Ⅲ study found no difference 
in response rates or quality of  life between the arms but 
did find an improvement of  median overall survival from 
5.91 to 6.24 mo (P = 0.038) with the addition of  erlotinib 
and the one year survival improved from 17% to 23% (P 
= 0.023)[14]. The very modest benefit in median survival (2 
wk) raises the question as to whether this is clinically rel-
evant although there is a tail of  increased survivors at one 
year. Tumour tissue was collected in this study from 184 
patients out of  569 patients with only 162 with sufficient 
tumour for immunohistochemistry, limiting the power 
to detect whether EGFR expression had any effect on 
outcome. Although a positive relationship between the 
development of  rash and survival was observed in this 
study suggesting that this may be a identify a favourable 
prognostic subgroup, a subsequent study that explored 
dose escalation of  erlotinib until development of  rash 
found no added benefit to standard fixed dose erlotinib 
when combined with gemcitabine[15]. Also of  note, a sub-
sequent SWOG phase Ⅲ trial using the monoclonal an-
tibody cetuximab as an anti-EGFR strategy in advanced 
pancreatic cancer found no additional benefit when 
added to gemcitabine[16].
Antiangiogenics have been tested in a number of  
phase Ⅲ trials in combination with gemcitabine. These 
include the anti-vascular endothelial growth factor (anti-
VEGF) monoclonal antibodies bevacizumab[17,18] and 
aflibercept[19] as well as the oral small molecule tyrosine 
kinase inhibitor axitinib[20,21]. These trials have been uni-
formly negative and suggest that targeting VEGF is an 
ineffective strategy in pancreatic cancer. Similarly, trials 
of  the matrix metalloproteinase inhibitors marimastat[22] 
and BAY 12-9566[23] have also been negative. A phase Ⅲ 
trial of  the multikinase inhibitor sorafenib in combina-
tion with gemcitabine was also negative[24], as was a study 
of  enzastaurin a PKCbeta and PI3K/AKT signalling in-
hibitor[25].
These trials have all taken a ‘‘one size fits all’’ approach 
to treatment of  advanced pancreatic cancer in enrolling 
unselected patients. With the recognition that pancreatic 
cancer is a biologically heterogenous disease, a person-
alised approach would mean selecting out patients into 
enriched groups with biomarker or genomic profiles of  
activated pathways that are more likely to respond to tar-
geted agents being tested therapeutically[26]. This approach 
has been taken with the randomised phase Ⅱ RECAP 
trial (NCT01423604) of  capecitabine in combination with 
placebo or ruxolitinib a JAK1 and JAK2 inhibitor in which 
patients with recurrent or treatment refractory pancreatic 
cancer has analysed a prespecified subgroup of  patients 
identified prospectively as likely to benefit from JAK inhi-
bition. Within this subgroup which is half  of  the random-
ized population the hazard ratio for survival was 0.47 with 
ruzolitinib with 6 mo survival being 42% and 11% for pla-
cebo[27]. This trial is yet to be formally reported but a phase 
Ⅲ study is expected to be launched soon. 
Current understanding of core signalling pathways in 
pancreatic cancer
Detailed molecular analysis of  pancreatic cancer began 
at the beginning of  the 21st century, with CDKN2A, 
SMAD4, TP53 and KRAS the first candidate genes iden-
tified[28-32]. In late 2008 Jones et al[33] published a seminal 
paper in Science detailing global genomic analysis of  24 
pancreatic cancers. In this paper, the authors made the 
case for 12 core signalling pathways that are genetically 
altered in the majority of  pancreas cancers. 
One pathway they highlighted was Wnt/Notch and 
Hedgehog signalling. Four years later, thanks to the inter-
national genome sequencing efforts described above, Bi-
ankin et al[34] published genomic data from 142 early stage 
pancreatic cancers. Although substantial heterogeneity 
was identified, 16 genes were significantly mutated. Reas-
suringly, some of  these were common to those identified 
by Jones et al[33] but additional novel mutated genes were 
identified. Of  these, the strongest signal was obtained 
from the SLIT/ROBO pathway of  axon guidance that 
was identified previously in 2003[35,36]. Further work on 
this pathway to establish its role in tumourigenesis of  
pancreatic cancer is ongoing. Clearly the ongoing chal-
lenge for biologists in this field is to determine drivers of  
pancreas cancer, understanding that there may be differ-
ent drivers in different cases. Using this method of  sepa-
rating pancreatic cancers into subgroups by driver has 
led us to test targeted, personalised treatment in animal 
models and also in human subjects.
Potential ‘‘actionable mutations’’ based on molecular 
profiling of pancreatic cancers
Several actionable changes have been identified in pan-
creas cancer; those with greatest potential clinical signifi-
cance are summarised in Table 1.
Some of  these were able to be verified with accred-
ited, confirmatory genomic tests that are available com-
mercially, such as KRAS mutation testing, BRCA1 and 
BRCA2 mutation testing and ATM mutation testing. It 
is envisaged that the future will see targeted sequencing 
panels for pancreas cancer being commercially available, 
accredited and clinically applicable with short timelines 
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Her2 as an example of an ‘‘actionable’’ mutation
The HER2 (human epidermal growth factor receptor)/
neu/ERBB2 gene is a member of  a family of  genes that 
and low cost. Others, such as Her2 upregulation, can be 
tested for using immunohistochemistry and in situ hybri-
disation. 
Table 1  Potentially ''actionable'' phenotypes and supporting evidence
Actionable 
phenotype
Therapeutic Rationale Molecular characterization
Gemcitabine 
responsive
Gemcitabine In PC, Phase Ⅲ trials showed benefit in adjuvant (DFS 
13.4 mo vs 6.9 mo) and palliative setting (MS 5.65 vs 
4.41)[6,87] 
High hENT1, hCNT1, hCNT3 
Phase Ⅲ data suggested that hENT1 correlated with response to 
Gemcitabine in adjuvant setting in PC[65,88], however this was not 
shown in the metastatic population[89] 
Anti-EGFR 
responsive
Erlotinib, 
Cetuximab
A Phase Ⅲ trial showed that Erlotinib plus 
Gemcitabine had an overall survival benefit (HR = 
0.82) compared with Gemcitabine alone in PC[14] 
Phase Ⅲ data did not show a difference in OS 
when Cetuximab was added to Gemcitabine in an 
unselected population with PC[16]
Classical subtype
PC cell lines with a “classical” subtype were shown to be more 
sensitive to Erlotinib[90] 
EGFR expression did not correlate with response to Cetuximab in 
patients with PC[16]
Taxane 
responsive
nab-Paclitaxel Phase Ⅲ data showed that the addition of nab-
Paclitaxel to Gemcitabine increased PFS (HR = 0.69) 
and OS (HR = 0.72) in the metastatic PC population[13]
SPARC expression (stromal) 
A phase Ⅰ/Ⅱ study showed that SPARC expression in the stroma 
correlated with survival[71]
5-FU 
responsive
5-Fluorouracil Small phase Ⅲ trials showed activity of 5-FU 
containing regimens in the metastatic population in 
PC[91,92]
5-FU was shown to prolong survival when used in 
the adjuvant setting in PC (HR = 0.7)[93]
Thymidylate Synthase
High intra-tumoural expression was shown to correlate with an 
increased benefit from 5-FU based chemotherapy in pre-clinical[94] 
and retrospective patient populations[95]
Irinotecan 
responsive
Irinotecan In PC, a small effect as monotherapy has been shown 
in the second-line setting[96], and a significant effect 
on OS was shown when used as part of FOLFIRINOX 
(HR = 0.57)[11]
Topoisomerase 1 expression
High topo 1 expression was associated with a larger benefit from 
Irinotecan containing regimens in metastatic colorectal cancer[97]
HER2 
amplified
Trastuzumab Has shown activity in HER-2 overexpressing breast 
and gastric cancers[39,98,99]
Phase Ⅱ trials do not show a benefit of adding 
Trastuzumab to Gemcitabine in PC (OS = 7 mo), 
however, no standardised approach to FISH testing 
was used[41,70]
HER2 amplification
Pre-clinical studies suggested that HER2 overexpression predicts a 
response to Trastuzumab in PC[100]
m-TOR 
responsive
Everolimus, 
Temsirolimus
A phase Ⅲ trial of Everolimus in renal cell cancer 
shows prolongation in PFS (PFS 4 mo vs 1.9 mo)[101]
Phase Ⅱ data showed minimal activity (OS = 4.5 
mo) of Everolimus for second line treatment in an 
unselected population of patients with metastatic 
PC[102]
A case study in a patient with PC and Peutz-Jeghers 
syndrome (SK11 deficient) responds to Everolimus[103]
P-TEN Deficient, High p-mTOR/p70S6, 
AKT amplified, STK11/LKB1 deficiency, PI3K mutation 
Pre clinical studies showed that p-TEN deficient cell lines are 
sensitive to m-TOR inhibitors[104]
Retrospective studies suggested that SK11, p-MTOR, p-70S6, 
PI3K and AKT can select tumours that will respond to m-TOR 
inhibitors[103,104-110]
VEGF 
inhibitor 
responsive
Sunitinib, 
Bevacizumab
Phase Ⅲ trial showed no benefit with adding 
Bevacizumab to Gemcitabine in an unselected 
population of patients with PC[17]
Phase Ⅱ data showed that maintenance Sunitinib 
after primary chemotherapy improved 2 yr OS (22.9% 
vs 7%) in the metastatic PC population[109]
CSF1R up-regulation, High HIF-α expression
In vitro studies showed CSF-1R up-regulation was associated with 
response to Sunitinib in AML[110]
High HIF-α predicted response to Sunitinib in a retrospective 
cohort in renal cell cancer[111]
DNA damage 
repair 
deficient
Platinum; 
MMC; PARP 
inhibitor
In vitro work showed that cells with defects in BRCA2 
are preferentially sensitive to PARP inhibitors[112]
Case reports of PC patients with BRCA2 deficient 
tumours respond to PARP[113,114]
Multiple clinical trials are on-going assessing the 
effects of PARP inhibition
DDR signature; mutation of DDR genes,
BRCA/ATM/PALB2
Loss of BRCA1 was associated with sensitivity to DNA damaging 
agents[115]
BRCA2 mutations were associated with improved response to 
platinum agents[116]
In vivo studies showed PALB2 inactivation was a determinant of 
response to DNA damaging agents in PC[114]
SMO inhibitor 
responsive
Saridegib, 
Vismodegib
A phase Ⅱ trial found that Saridegib plus 
Gemcitabine was no better than Gemcitabine alone 
in an unselected population of metastatic PC patients 
(data not published)[117]
In vivo studies show SMO inhibitors block metastasis 
formation in pancreatic cancer[118]
Gli1 and PTCH1 transcript levels
GLI1 mRNA may predict response to SMO inhibitors in pancreatic 
cancer in vivo[119]
High Gli1/PTCH1 transcript levels were correlated with response 
to SMO inhibitors in CLL[120]
PC: Pancreatic cancers; EGFR: Epidermal growth factor receptor; VEGF: Vascular endothelial growth factor; DFS: Disease-free survival; OS: Overall 
survival.
Sjoquist KM et al . Challenges of personalising pancreas cancer treatment
7853 June 28, 2014|Volume 20|Issue 24|WJG|www.wjgnet.com
play a role in regulating cell growth. HER2 signalling pro-
motes cell proliferation through the RAS-MAPK pathway 
and inhibits cell death through the phosphatidylinositol 
3’-kinase-AKT-mammalian target of  rapamycin (mTOR) 
pathway. Although HER2 overexpression has been de-
scribed in a variety of  human malignant conditions, gene 
amplification is uncommon except in breast and gastric 
cancer[37]. Anti-HER2 therapy is clinical indicated and ef-
fective for both HER2 amplified breast[38] and gastric[39] 
cancers. There is growing evidence that HER2 is an im-
portant biomarker and key driver of  tumourigenesis in 
pancreatic cancer.
Recent evidence suggests HER2 amplification oc-
curs in 2% of  pancreatic ductal adenocarcinoma, and 
may potentially respond to anti-HER2 therapy[37], simi-
lar to HER2-amplified breast cancer. On a molecular 
level, HER2-amplified pancreatic cancers demonstrated 
a mRNA expression profile which clustered with the 
HER2-amplified intrinsic subtype of  breast cancer us-
ing the PAM50 classifier. Clinically, HER2-amplified 
pancreatic cancers showed an atypical metastatic pattern 
characterized by spread to the lungs and brain with avoid-
ance of  the liver, not unlike the pattern of  spread seen 
in HER2-amplified breast cancer. These findings suggest 
that HER2 is likely to be the main driver of  tumorigen-
esis in this subgroup of  pancreatic cancer, analogous to 
HER2-amplified breast cancer and may respond to anti-
HER2 therapy. 
Three clinical trials have assessed anti-Her2 therapy in 
pancreatic cancer. All 3 were single arm phase Ⅱ trials util-
ising anti-Her2 agents active in other cancers in conjunc-
tion with traditional cytotoxics. Only 2 of  the trials selected 
patients based on Her2 status, and utilised immunohisto-
chemistry alone to detect HER2 overexpression[40-42]. 
In Safran’s first study patients with HER2 overex-
pressing metastatic pancreatic cancers were recruited and 
showed a response rate of  only 6% which was consid-
ered as not significantly different from historical controls 
of  gemcitabine alone[40]. The majority of  the patients 
recruited however had HER2 2+ tumors. In Safran’s sec-
ond study lapatinib (a dual HER1 and HER2 inhibitor) 
and gemcitabine were given to an unselected population 
of  patients with metastatic pancreatic cancer[42]. The 
study was terminated after 6 mo due to poor response 
rate. Harder et al[41] recruited 17 patients with HER2 ex-
pressing metastatic pancreatic cancer for trastuzumab 
and capecitabine, and this study closed prematurely due 
to lower than expected prevalence of  HER2 3+ tumours 
and therefore slow accrual.
The selection of  patients was based on HER2 expres-
sion using immunohistochemstry alone and these were 
not standardized assays performed in reference labora-
tories. As a result it is possible that the use of  non-stan-
dardised assys performed outside accredited reference 
laboratories overestimated HER2 positivity. The likely 
overestimation of  HER2 positivity underpowered the tri-
als and makes a negative result difficult to interpret. 
Identifying HER2 overexpressing pancreatic cancers 
(PC) by genomic profiling has the potential to identify a 
cohort more likely to benefit from anti-HER2 therapy. 
This enrichment strategy is being utilised in the recently 
opened IMPaCT (Individualised Molecular Pancreatic 
Cancer Therapy) trial (Table 2) of  which several authors 
are investigators.
Preclinical trials of repurposed drugs in patient-derived 
xenografts
In order to maximize benefit to patients clinical trials 
should be conducted in populations based on molecular 
characteristics[43]. This highlights the importance of  bio-
marker driven therapeutic development. Such trials are 
expensive, labour intensive and pose significant logistical 
difficulties which in PC, are compounded by the rapid-
ity of  clinical deterioration and the small percentage of  
patients who are well enough to receive more than one 
line of  chemotherapy. Using patient derived xenografts 
presents an attractive option to test potential biomarkers 
and partnered therapeutic interventions.
Xenograft models derived from established tumour 
cell lines may not fully recapitulate the complexities of  
human disease and therefore may not be the ideal medi-
um with which to test novel therapeutics[44-46]. In addition 
the vast majority of  cell lines that have been used in the 
past do not have associated germline sequence data. As a 
consequence, the accuracy of  genomic aberrations iden-
tified by comparing to a reference sequence is not suf-
ficient for subsequent testing of  genotype-guided treat-
ment strategies. Genetically engineered mouse models 
(GEMM) will develop PC predictably and can be used to 
study pancreatic carcinogenesis[47]. However, Singh et al[48] 
showed that the PDAC Pdx1-Cre LSL-KrasG12Dp16/p19fl/fl 
GEMM had a greater response to gemcitabine than typi-
cally observed in the patient population, suggesting these 
models too lack the heterogeneity and complexity of  the 
human condition.
Primary xenografts are generated directly from en-
graftment of  individual human tumour tissue into se-
verely immunocompromised mice [nonobese diabetic 
/severe combined immunodeficiencies IL2rg -/- (NSG) 
mice] allowing efficient engraftment of  the tumour[49,50]. 
These have been shown to faithfully represent the his-
topathological, biological and genomic characteristics of  
the primary tumour[51,52]. These models may represent 
valuable tools for testing novel therapies. Primary xeno-
graft models have been used to test novel therapies in 
childhood leukaemia[53-55] and neuroblastoma[56,57]. More 
recently in PC, primary xenografts have been used to test 
the efficacy of  sorafenib and everolimus alone and in 
combination[58]. 
The generation of  primary xenografts provides a re-
newable and valuable resource with which multiple treat-
ments may be studied. Large pre-clinical trials may be 
designed where a specific tumour of  interest may be ex-
amined for its sensitivity to numerous different therapies 
or efficacy of  a single novel therapy may be examined in 
a range of  tumours with different molecular profiles. The 
Sjoquist KM et al . Challenges of personalising pancreas cancer treatment
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Identification of  a biomarker of  radiosensitivity has 
been explored in other tumour sites. The XRCC1 (X-ray 
repair cross-complementing group 1) protein is involved 
in base excision repair. A single nucleotide polymorphism 
known as Arg399Gln has been shown to affect radiosen-
sitivity. The ECOG 1201 Phase Ⅱ trial analysed patients 
to determine whether the presence of  this allele affected 
complete response rates after neoadjuvant cisplatin based 
chemoradiotherapy in oesophageal adenocarcinoma[62]. 
Fifty-two percent of  patients had the Arg399Gln allele 
and only 6% of  those had a complete response at time 
of  surgery 5 wk after completion of  their neoadjuvant 
treatment. The odds ratio for failing to undergo a com-
plete pathological response in the presence of  this allele 
was 5.37 (P = 0.062). This did not translate to a reduction 
in disease free or overall survival though it does suggest 
there are certain patients who are more likely to respond 
to radiotherapy.
Optimising drug delivery with predictive biomarkers
The co-development of  novel chemotherapeutic and 
therapeutic strategy with companion diagnostics is the 
paradigm of  modern clinical oncology. Outcomes from 
these efforts have been somewhat mixed to date, and the 
reasons are many and complex. For the purpose of  this 
review, the authors will only concentrate on two drugs 
that have been approved for use in pancreatic cancer.
Gemcitabine: The putative biomarkers of  gemcitabine 
responsiveness include nucleoside transporters such as 
hENT1, hCNT1/3 and kinases involved in gemcitabine 
metabolism such as deoxycytidine kinase[63,64]. The most 
studied biomarker of  therapeutic responsiveness to date 
in PC is hENT1, a membranous equilibrative nucleo-
side transporter encoded by the SLC29A1 gene. There 
is promising evidence to support the role of  hENT1 in 
gemcitabine responsiveness in PC cells both in vitro and 
In vivo, but its precise role as a predictive biomarker in 
the clinic has not been well established, with conflicting 
results reported. Small cohort studies and retrospective 
analysis of  large Phase Ⅲ randomised-controlled tri-
als (RCT), such as RTOG 9704 and ESPAC 1/3 have 
supported its role as a predictive biomarker of  adju-
vant gemcitabine responsiveness, where patients with 
hENT1 positive tumour had significant survival benefit 
from adjuvant gemcitabine as compared to patients 
with low hENT1 tumours[65,66]. However, a recent Phase 
Ⅱ RCT stratified by hENT1 expression (LEAP: Low 
hENT1 and Adenocarcinoma of  the Pancreas) compar-
ing gemcitabine vs CO-101 (lipophilic gemcitabine) in 
metastatic PC failed to demonstrate this in metastatic 
disease[4]. Though the reasons for this are still unclear, 
the discrepancy may be due to the use of  different 
hENT1 antibodies for immunohistochemistry, and/or 
perhaps the significance of  hENT1 as a predictive 
biomarker is different in the metastatic as compared 
to the adjuvant setting. LEAP was the first purposely 
designed biomarker stratified trial in PC with prospec-
tive tissue acquisition, further analysis of  the available 
tissue samples may offer more insight into gemcitabine 
responsiveness biomarkers.
nab -Paclitaxel (Abraxane®): Secreted Protein Acid 
and Rich in Cysteine (SPARC, also known as osteo-
nectin) regulates extracellular matrix modeling and 
deposition and may act as a tumour suppressor or an 
oncogenic driver depending on its differential expres-
sion in epithelial and stromal compartments in different 
cancer types[67]. High stromal and low epithelial expres-
sion of  SPARC has been shown to be a poor prognos-
tic biomarker in PC[68,69] and based on its hypothesised 
function as an albumin “sticker”, it was developed as a 
therapeutic target for nab-paclitaxel to enable “stromal 
depletion” and in turn, to improve drug delivery. A posi-
tive phase Ⅰ/Ⅱ study of  gemcitabine plus nab-paclitaxel 
demonstrated in a biological sub-study that SPARC 
expression in the stroma, but not in the epithelium, co-
segregated with improved survival in PC, and hence a 
candidate predictive biomarker for nab-paclitaxel respon-
siveness[70]. This led to the recently reported Phase Ⅲ 
MPACT (Metastatic Pancreatic Adenocarcinoma Clinical 
Trial) RCT comparing gemcitabine vs gemcitabine plus 
nab-paclitaxel which demonstrated the significant addi-
tion survival benefit of  nab-paclitaxel in patients with 
metastatic PC[71]. However, data concerning SPARC as 
a predictive biomarker of  nab-paclitaxel responsiveness 
are not currently available. Although the relationship 
between SPARC expression and nab-paclitaxel respon-
siveness is still evolving, these proof-of-concept data 
suggest it warrants further exploration. 
Improving treatment delivery: Targeting stroma 
There is mounting evidence that stromal factors may be 
crucially important not only in determining the develop-
ment and behaviour of  carcinoma, but in influencing 
treatment response and, ultimately, prognosis. Stromal 
and epithelial cells may interact through direct cell-
cell contact, or via paracrine signaling, and various non-
cellular components in the stroma may influence either 
or both cell types. Many of  these factors may contribute 
to cancer progression and metastasis through altered cell 
adhesion, epithelial-mesenchymal transition (EMT), ma-
trix remodeling (facilitating tumour cell migration), and 
neovascularisation. These concepts have been examined 
in more detail elsewhere[72]. 
Individual differences in gene expression have been 
demonstrated within the stromal component of  breast 
tumours, and these different phenotypes correlated with 
clinical outcome[73,74]. Differential expression of  some of  
these same genes at the protein level appears to correlate 
with tumour regression in irradiated rectal carcinoma 
(Hemmings, unpublished data). One such protein is 
SPARC (Secreted Protein Acidic and Rich in Cysteine), a 
matricellular protein which modulates cell-cell and cell-
matrix interactions, as described previously. Treatment 
with SPARC can block fibroblast activation and may 
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serve to inhibit angiogenesis[75]. There is some evidence 
that SPARC may act as a chemosensitiser by potentiating 
apoptosis[76]. SPARC may be upregulated in pancreatic 
cancer, and suppressing its expression may inhibit cancer 
cell migration, offering a potential therapeutic target[77]. 
Modulation of  other matricellular proteins has also been 
shown (at least in a murine model) to alter chemotherapy 
response, without directly altering drug delivery[78], and 
the addition of  agents which modify the tumour stroma 
may enhance chemotherapy response in clinical cases of  
operable pancreatic cancer[79].
Another important stromal variable is the host im-
mune response to invading tumour cells. Whilst generally 
thought to be part of  the host’s armamentarium against 
cancer, it has become clear that inflammatory cells may 
promote the formation and progression of  some tu-
mours, and the balance of  pro- and anti-tumour effects 
varies between individuals as well as between different 
tumour types. In pancreatic cancer, tumour-infiltrating 
TH17 (lymphoid) cells may act on stroma to induce an-
giogenesis, as well as activating other tumour-promoting 
transcription factors[80]. In one model, tumours which 
were resistant to VEGF inhibitors were rendered sensi-
tive by inhibition of  TH17 effector function, suggesting 
that immunomodulation may improve the efficacy of  
antiangiogenic treatments[81]. Similarly, tumour-associated 
macrophages (TAMs) may produce various growth fac-
tors as well as proteases which degrade the extracellular 
matrix, facilitating tumour invasion and angiogenesis[73], 
and may promote EMT in pancreatic cancer cells[82]. 
Transition of  normal macrophages to tumour-promoting 
TAMs may be induced by IL-4 produced by pancreatic 
carcinoma cells[83], again offering a possible therapeutic 
target, and other inflammatory mediators may serve as 
biomarkers of  prognosis in patients with advanced pan-
creatic carcinoma[84].
DEVELOPING THE EVIDENCE BASE FOR 
A ‘‘PERSONALISED APPROACH’’ 
Many challenges exist in developing the evidence base for 
a ‘‘personalised approach’’ to PC treatment. These include: 
appropriate design of  clinical trials; development, inter-
pretation and accreditation of  standardised tests; match-
ing appropriate patients to suitable trials; and minimising 
turn around time of  new molecular based diagnostic tests 
required for trial eligibility and ultimately treatment selec-
tion[26,85,86]. A number of  clinical trials examining different 
aspects of  personalised treatment for pancreatic cancer 
are ongoing (Table 2). Biobanking of  tissue samples 
linked to clinical outcomes data is possible within clinical 
trials and community cohorts. Such resources hold signifi-
cant potential for true translational research. 
Molecular profiling of tumours and the role of biobanks
Next generation sequencing is providing unprecedented 
opportunities to uncover the underlying genetic pathways 
driving cancer and is accelerating the drive towards per-
sonalized medicine. Human specimens that are analyzed 
using these technology platforms are a critical resource 
for basic and translational research in cancer because 
they are a direct source of  molecular data from which 
targets for therapy, detection, and prevention are identi-
fied. The recent Federal Drug Administration approval 
of  next generation sequencing platforms for diagnostic 
use (http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm375742.htm) and the rapidly 
falling costs of  whole genome sequencing will bring this 
technology into the clinic in the near future.
Biobanking has the potential to be a powerful plat-
form for health innovation and knowledge generation, as 
biospecimens represent essential materials that fuel the 
advance of  technology, scientific and medical research. 
This has stimulated a growing demand for appropriately 
qualified, well annotated biospecimens world-wide. 
However, establishing a biobank of  value, presents 
unique ethical, logistical, scientific, informational, and 
financial challenges in tissue acquisition and resource de-
velopment. To be of  maximum value tissue samples and 
analytical methods must be ‘‘fit for purpose’’ and repro-
ducible.
Controlling pre-analytical variables is critical to ensure 
that the results of  multidimensional high-throughput 
profiling are accurate and reproducible. The Australian 
Pancreatic Cancer Genome Initiative, an Australian led, 
international effort to characterise the genome of  pan-
creatic cancer, has led international efforts to harmonise 
and standardize biospecimen collection, processing and 
downstream application. Factors critical to the success 
of  this initiative include using best practice to guide 
processes, collection of  multiple aliquots of  specimens, 
ensuring all samples have a reference germline sample 
and expanding the repertoire to include the development 
of  patient derived xenografts and cell lines. It is crucial to 
set appropriate standards from the projects initiation, and 
the human aspects of  this complex enterprise cannot be 
underestimated to ensure quality samples that accurately 
represent the spectrum of  cancer. 
Meeting the challenges of  biospecimen quality and 
interoperability requires a more modern approach to 
biobanking. Modern biobanking sees a new type of  bio-
specimen emerge: where biospecimens are collected at 
distinct time points, and in a pre-specified clinical con-
text. These samples are comprehensively annotated with 
clinico-pathological and treatment data, and linked to 
genomic and molecular data sets. Procurement of  these 
types of  samples requires a new organisational structure 
that incudes specific clinical disciplines such as interven-
tional radiology and molecular pathology.
CONCLUSION 
Recent advances in the treatment of  pancreatic cancer 
have evolved through greater understanding of  clinical 
tumour biology. None of  this would be possible with-
out access to tumour tissues. Biospecimen collection for 
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future research is becoming an integral part of  trials and 
increasingly part of  practice. Appropriate methods for 
collection, analysis and annotation of  specimens are criti-
cal for maximising benefit from this valuable resource 
and ensuring reliability and reproducibility of  results.
There is still much progress to be made in improving 
outcomes for patients with pancreatic cancer. Oncolo-
gists are increasingly recognising the importance of  bio-
specimen collection to facilitate precision medicine. To 
make this a reality in practice, engagement of  patients 
and other related clinicians( gastroenterologists, radiolo-
gists and pathologists) is vital. Acceptability to patients in 
routine practice is a crucial step in moving not just from 
bench to bedside but from trial to clinic.
The contribution of  patients in allowing their speci-
mens to be accessed for research cannot be undervalued. 
At both global and individual levels, for contribution to 
research and for personalisation of  treatment, tissue is 
-and will continue to be- an important issue.
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